Literature DB >> 18552165

Integrin alphavbeta3 acts downstream of insulin in normalization of interstitial fluid pressure in sepsis and in cell-mediated collagen gel contraction.

Oyvind Sverre Svendsen1, Asa Lidén, Torbjørn Nedrebø, Kristofer Rubin, Rolf K Reed.   

Abstract

The administration of insulin is recommended to patients with severe sepsis and hyperglycemia. Previously, we demonstrated that insulin may have direct anti-inflammatory properties and counteracted fluid losses from the circulation by normalizing the interstitial fluid pressure (P(IF)). P(IF) is one of the Starling forces determining fluid flux over the capillary wall, and a lowered P(IF) is one of the driving forces in early edema formation in inflammatory reactions. Here we demonstrate that insulin restores a lipopolysaccharide (LPS)-lowered P(IF) via a mechanism involving integrin alpha(v)beta(3). In C57 black mice (n = 6), LPS lowered P(IF) from -0.2 +/- 0.2 to -1.6 +/- 0.3 (P < 0.05) and after insulin averaged -0.8 +/- 0.2 mmHg (P = 0.098 compared with after LPS). Corresponding values in wild-type BALB/c mice (n = 5) were -0.8 +/- 0.1, -2.1 +/- 0.3 (P < 0.05), and -0.8 +/- 0.3 mmHg (P < 0.05 compared with LPS) after insulin administration. In BALB/c integrin beta(3)-deficient (beta(3)(-/-)) mice (n = 6), LPS lowered P(IF) from -0.1 +/- 0.2 to -1.5 +/- 0.3 mmHg (P < 0.05). Insulin did not, however, restore P(IF) in these mice (averaged -1.7 +/- 0.3 mmHg after insulin administration). Cell-mediated collagen gel contraction can serve as an in vitro model for in vivo measurements of P(IF). Insulin induced alpha(v)beta(3)-integrin-dependent collagen gel contraction mediated by C2C12 cells. Our findings suggest a beneficiary effect of insulin for patients with sepsis with regard to the fluid balance, and this effect may in part be due to a normalization of P(IF) by a mechanism involving the integrin alpha(v)beta(3).

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18552165      PMCID: PMC2519195          DOI: 10.1152/ajpheart.00161.2008

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  32 in total

1.  Modulation of heart fibroblast migration and collagen gel contraction by IGF-I.

Authors:  S Kanekar; T K Borg; L Terracio; W Carver
Journal:  Cell Adhes Commun       Date:  2000

2.  Intensive insulin therapy in critically ill patients.

Authors:  G van den Berghe; P Wouters; F Weekers; C Verwaest; F Bruyninckx; M Schetz; D Vlasselaers; P Ferdinande; P Lauwers; R Bouillon
Journal:  N Engl J Med       Date:  2001-11-08       Impact factor: 91.245

3.  alpha11beta1 integrin is a receptor for interstitial collagens involved in cell migration and collagen reorganization on mesenchymal nonmuscle cells.

Authors:  C F Tiger; F Fougerousse; G Grundström; T Velling; D Gullberg
Journal:  Dev Biol       Date:  2001-09-01       Impact factor: 3.582

Review 4.  New and active role of the interstitium in control of interstitial fluid pressure: potential therapeutic consequences.

Authors:  H Wiig; K Rubin; R K Reed
Journal:  Acta Anaesthesiol Scand       Date:  2003-02       Impact factor: 2.105

5.  A secreted collagen- and fibronectin-binding streptococcal protein modulates cell-mediated collagen gel contraction and interstitial fluid pressure.

Authors:  Asa Lidén; Tijs van Wieringen; Jonas Lannergård; Anja Kassner; Dick Heinegård; Rolf K Reed; Bengt Guss; Kristofer Rubin
Journal:  J Biol Chem       Date:  2007-11-13       Impact factor: 5.157

6.  Mice lacking beta3 integrins are osteosclerotic because of dysfunctional osteoclasts.

Authors:  K P McHugh; K Hodivala-Dilke; M H Zheng; N Namba; J Lam; D Novack; X Feng; F P Ross; R O Hynes; S L Teitelbaum
Journal:  J Clin Invest       Date:  2000-02       Impact factor: 14.808

Review 7.  Integrin alpha V beta 3 as a target for treatment of rheumatoid arthritis and related rheumatic diseases.

Authors:  R L Wilder
Journal:  Ann Rheum Dis       Date:  2002-11       Impact factor: 19.103

8.  A novel function of insulin in rat dermis.

Authors:  Torbjørn Nedrebø; Tine V Karlsen; Gerd S Salvesen; Rolf K Reed
Journal:  J Physiol       Date:  2004-07-02       Impact factor: 5.182

9.  Neurogenic inflammation in mice deficient in heparin-synthesizing enzyme.

Authors:  Tine V Karlsen; Vegard V Iversen; Erik Forsberg; Lena Kjellén; Rolf K Reed; Eli-Anne B Gjerde
Journal:  Am J Physiol Heart Circ Physiol       Date:  2003-11-06       Impact factor: 4.733

10.  Integrin alphavbeta3 mediates platelet-derived growth factor-BB-stimulated collagen gel contraction in cells expressing signaling deficient integrin alpha2beta1.

Authors:  Gunilla Grundström; Deane F Mosher; Takao Sakai; Kristofer Rubin
Journal:  Exp Cell Res       Date:  2003-12-10       Impact factor: 3.905

View more
  4 in total

Review 1.  Multifaceted role of insulin-like growth factors and mammalian target of rapamycin in skeletal muscle.

Authors:  Robert A Frost; Charles H Lang
Journal:  Endocrinol Metab Clin North Am       Date:  2012-05-10       Impact factor: 4.741

2.  Increased fibrosis and interstitial fluid pressure in two different types of syngeneic murine carcinoma grown in integrin β3-subunit deficient mice.

Authors:  Tomas Friman; Renata Gustafsson; Linda B Stuhr; Jean Chidiac; Nils-Erik Heldin; Rolf K Reed; Ake Oldberg; Kristofer Rubin
Journal:  PLoS One       Date:  2012-03-30       Impact factor: 3.240

3.  The streptococcal collagen-binding protein CNE specifically interferes with alphaVbeta3-mediated cellular interactions with triple helical collagen.

Authors:  Tijs van Wieringen; Sebastian Kalamajski; Asa Lidén; Dominique Bihan; Bengt Guss; Dick Heinegård; Richard W Farndale; Kristofer Rubin
Journal:  J Biol Chem       Date:  2010-09-13       Impact factor: 5.157

4.  Integrin αV β3 can substitute for collagen-binding β1 -integrins in vivo to maintain a homeostatic interstitial fluid pressure.

Authors:  Åsa Lidén; Tine Veronika Karlsen; Bengt Guss; Rolf K Reed; Kristofer Rubin
Journal:  Exp Physiol       Date:  2018-05-01       Impact factor: 2.969

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.